Experienced Patent Litigator Strengthens Firm’s Pharmaceutical, Biotech and Complex IP Litigation Capabilities

Meunier Carlin & Curfman LLC (MCC) is pleased to announce that Shannon Clark has joined the firm as a Principal, further strengthening its patent litigation practice and expanding its capabilities in the pharmaceutical, biotechnology and chemical industries.

Ms. Clark brings extensive experience representing leading life sciences companies in complex patent disputes, with particular expertise in litigation arising under the Hatch-Waxman Act, including Abbreviated New Drug Application (ANDA) cases. She has managed patent litigation matters from inception through trial and has served as lead trial counsel in high-stakes disputes involving commercially significant pharmaceutical products and innovation technologies.

“Shannon bring an exceptional combination of technical knowledge, courtroom experience, and strategic insight to our litigation team,” said managing partner, Drew Meunier. “Her experience representing clients in complex pharmaceutical and biotechnology disputes aligns perfectly with our firm’s commitment to delivering sophisticated, results-driven intellectual property counsel. We are thrilled to welcome her to MCC!”

Throughout her career, Ms. Clark has represented prominent pharmaceutical and biotechnology companies. Her experience encompasses disputes involving pharmaceutical treatments, biologic technologies, and innovative drug products, providing her with a deep understanding of the legal, technical, and commercial challenges facing her clients.

Prior to joining MCC, she was a partner at Venable LLP. She earned her J.D., magna cum laude, from Seton Hall University, where she was inducted into the Order of the Coif. She received her B.S. in Biology, cum laude, from Birmingham-Southern College.